glp-1 in obesity The Role of Receptor Agonists Insulin Resistance with Concomitant Treatment in Polycystic Ovary Syndrome Only one in 12 remain
Description
The Danish pharma giant announced on Tuesday a new agreement with Vivani to evaluate its lead semaglutide implant, NPM-139
For some individuals, long-term treatment may make sense
According to the research focused on those with alcohol use disorder, the latest study, published in The BMJ , casts a much wider net, looking at the effects GLP-1s have on other substance use disorders, including cannabis, cocaine, nicotine, and opioids
Semaglutide is the active ingredient
In a separate working paper, we propose a value-based approach to expand GLP-1 coverage for weight loss
Those taking tirzepatide, achieved an additional 18.4% WL from randomisation to 72 weeks compared to those taking placebo who experienced weight regain of 2.5% [48]
